(function(){
			var content_array=["<p><strong>About<\/strong>&nbsp;<strong>VX-787<\/strong>&nbsp;<\/p>\r\n<p>VX-787 is a first-in-class, influenza A-specific, oral polymerase  inhibitor. It is the first and most advanced example of a novel mode of  action (MOA) direct acting antiviral working through the influenza virus  PB2 polymerase subunit. Targeting an alternative part of the viral  replication process may help ensure that this new medicine can  successfully treat strains of the influenza virus which may be resistant  to existing antiviral drugs with other MOAs.<\/p>\r\n<p>VX-787 has demonstrated potent and rapid in-vitro antiviral activity  on all Vertex tested influenza A strains to date, including oseltamivir  (Tamiflu&reg;) resistant strains.[2]&nbsp; Initial clinical  assessments of VX-787 have also been promising. Phase I studies  demonstrated the molecule was well tolerated in healthy volunteers  providing a pharmacokinetic profile supportive of once daily dosing.[2]  &nbsp;Vertex has also completed a Phase IIA challenge study that showed  statistically significant improvements in viral and clinical  measurements of influenza A infection and demonstrated clinical proof of  concept.[3]<\/p>\r\n<p><strong>About Influenza<\/strong> &nbsp;<\/p>\r\n<p>Influenza occurs globally, with an average of 5-10 percent of adults  and 20-30 percent of children becoming infected with the virus each  year. Worldwide, annual influenza epidemics are estimated to result in  about 3 to 5 million cases of severe illness, and about 250,000 to  500,000 deaths.[4] Yearly influenza epidemics can seriously  affect all populations, but the highest risk of complications occur  among children younger than age 2 years, adults aged 65 years or older,  pregnant women, and people of any age with certain medical conditions,  such as chronic heart, lung, kidney, liver, blood or metabolic diseases  (such as diabetes), or weakened immune systems.[4]<\/p>\r\n<p>The treatment of influenza consists of antiviral medications that  have been shown in clinical studies to shorten the disease and reduce  the severity of symptoms if taken within two days of infection, however,  there is a significant need for new medicines targeting flu that  provide a wider treatment window, greater efficacy and faster onset of  action.<\/p>\r\n<p><strong>About Janssen<\/strong> &nbsp;<\/p>\r\n<p>At Janssen, we are dedicated to addressing and solving some of the   most important unmet medical needs of our time in infectious diseases   and vaccines, oncology, immunology, neuroscience, and cardiovascular and   metabolic diseases. Driven by our commitment to patients, we develop   innovative products, services and healthcare solutions to help people   throughout the world. &nbsp;<\/p>\r\n<p>Janssen Pharmaceuticals, Inc. is part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson.<\/p>\r\n<p><em>(This press release contains \"forward-looking statements\" as   defined in the Private Securities Litigation Reform Act of 1995. The   reader is cautioned not to rely on these forward-looking statements.   These statements are based on current expectations of future events. If   underlying assumptions prove inaccurate or unknown risks or   uncertainties materialize, actual results could vary materially from the   expectations and projections of Janssen Pharmaceuticals, Inc. and\/or   Johnson &amp; Johnson.<\/em> &nbsp;&nbsp;<\/p>\r\n<p><em>Risks and uncertainties include, but are not limited to: economic   factors, such as interest rate and currency exchange rate  fluctuations;  competition, including technological advances, new  products and patents  attained by competitors; challenges inherent in  new product  development, including obtaining regulatory approvals;  challenges to  patents; changes in behavior and spending patterns or  financial distress  of purchasers of health care products and services;  changes to  governmental laws and regulations and domestic and foreign  health care  reforms; general industry conditions including trends  toward health care  cost containment; and increased scrutiny of the  health care industry by  government agencies.<\/em>&nbsp;&nbsp;<\/p>\r\n<p><em>A further list and description of these risks, uncertainties and   other factors can be found in Johnson &amp; Johnson's Annual Report on   Form 10-K for the fiscal year ended December 29, 2013, including in   Exhibit 99 thereto, and our subsequent filings with the Securities and   Exchange Commission. Copies of these filings are available online at&nbsp;<\/em><a rel=\"nofollow\" href=\"http:\/\/www.sec.gov\/\" target=\"_blank\"><em>http:\/\/www.sec.gov<\/em><\/a><em>,&nbsp;<\/em><a rel=\"nofollow\" href=\"http:\/\/www.jnj.com\/\" target=\"_blank\"><em>http:\/\/www.jnj.com<\/em><\/a><em>&nbsp;or on request from Johnson &amp; Johnson.<\/em>&nbsp; <em>None   of the Janssen Pharmaceutical Companies nor Johnson &amp; Johnson   undertakes to update any forward-looking statements as a result of new   information or future events or developments.)<\/em><\/p>\r\n<p>1. World Health Organization. Influenza. Available at: <a rel=\"nofollow\" href=\"http:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/influenza\" target=\"_blank\">http:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/influenza<\/a>. Last accessed June 2014<\/p>\r\n<p>2. Vertex. Data on file.<\/p>\r\n<p>3. Vertex. VX-787 Showed Significant Antiviral Activity and Reduced   the Severity and Duration of Influenza Symptoms in Phase 2 Challenge   Study. Available at: <a rel=\"nofollow\" href=\"http:\/\/investors.vrtx.com\/releasedetail.cfm?releaseid=744857\" target=\"_blank\">http:\/\/investors.vrtx.com\/releasedetail.cfm?releaseid=744857<\/a>. Last accessed June 2014.<\/p>\r\n<p>4. World Health Organization. Influenza (Seasonal). Available at: <a rel=\"nofollow\" href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/\" target=\"_blank\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/<\/a>. Last accessed June 2014.<\/p>"];
			$("#dvExtra").html(content_array[0]);})();